» Articles » PMID: 39223418

Lysosomal Dysfunction in α-synuclein Pathology: Molecular Mechanisms and Therapeutic Strategies

Overview
Publisher Springer
Specialty Biology
Date 2024 Sep 2
PMID 39223418
Authors
Affiliations
Soon will be listed here.
Abstract

In orchestrating cell signaling, facilitating plasma membrane repair, supervising protein secretion, managing waste elimination, and regulating energy consumption, lysosomes are indispensable guardians that play a crucial role in preserving intracellular homeostasis. Neurons are terminally differentiated post-mitotic cells. Neuronal function and waste elimination depend on normal lysosomal function. Converging data suggest that lysosomal dysfunction is a critical event in the etiology of Parkinson's disease (PD). Mutations in Glucosylceramidase Beta 1 (GBA1) and leucine-rich repeat kinase 2 (LRRK2) confer an increased risk for the development of parkinsonism. Furthermore, lysosomal dysfunction has been observed in the affected neurons of sporadic PD (sPD) patients. Given that lysosomal hydrolases actively contribute to the breakdown of impaired organelles and misfolded proteins, any compromise in lysosomal integrity could incite abnormal accumulation of proteins, including α-synuclein, the major component of Lewy bodies in PD. Clinical observations have shown that lysosomal protein levels in cerebrospinal fluid may serve as potential biomarkers for PD diagnosis and as signs of lysosomal dysfunction. In this review, we summarize the current evidence regarding lysosomal dysfunction in PD and discuss the intimate relationship between lysosomal dysfunction and pathological α-synuclein. In addition, we discuss therapeutic strategies that target lysosomes to treat PD.

Citing Articles

Epigallocatechin-3-Gallate, Quercetin, and Kaempferol for Treatment of Parkinson's Disease Through Prevention of Gut Dysbiosis and Attenuation of Multiple Molecular Mechanisms of Pathogenesis.

Kalu A, Ray S Brain Sci. 2025; 15(2).

PMID: 40002477 PMC: 11853474. DOI: 10.3390/brainsci15020144.


Targeting the Interplay Between Autophagy and the Nrf2 Pathway in Parkinson's Disease with Potential Therapeutic Implications.

Liu M, Liu S, Lin Z, Chen X, Jiao Q, Du X Biomolecules. 2025; 15(1).

PMID: 39858542 PMC: 11764135. DOI: 10.3390/biom15010149.

References
1.
Yang Q, Mao Z . Dysregulation of autophagy and Parkinson's disease: the MEF2D link. Apoptosis. 2010; 15(11):1410-4. DOI: 10.1007/s10495-010-0475-y. View

2.
Cuervo A, Stefanis L, Fredenburg R, Lansbury P, Sulzer D . Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004; 305(5688):1292-5. DOI: 10.1126/science.1101738. View

3.
Ambrosi G, Ghezzi C, Zangaglia R, Levandis G, Pacchetti C, Blandini F . Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells. Neurobiol Dis. 2015; 82:235-242. DOI: 10.1016/j.nbd.2015.06.008. View

4.
Alcalay R, Levy O, Waters C, Fahn S, Ford B, Kuo S . Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain. 2015; 138(Pt 9):2648-58. PMC: 4564023. DOI: 10.1093/brain/awv179. View

5.
Klucken J, Poehler A, Ebrahimi-Fakhari D, Schneider J, Nuber S, Rockenstein E . Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway. Autophagy. 2012; 8(5):754-66. PMC: 3378419. DOI: 10.4161/auto.19371. View